Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 1;13(8):5349-5354.
doi: 10.21037/qims-23-137. Epub 2023 Jun 5.

Contrast-enhanced mammography-guided biopsy: technique and initial outcomes

Ya-Chun Tang  1   2 , Yun-Chung Cheung  1   2
Affiliations

Contrast-enhanced mammography-guided biopsy: technique and initial outcomes

Ya-Chun Tang et al. Quant Imaging Med Surg. .

Abstract

Contrast-enhanced mammography-guided biopsy (CEM-Bx), a novel technique for diagnosing suspicious enhanced lesions, was commercialized for clinical application in 2021; however, there are only a few publications documenting this technique in the existing literature. The aim of this study was to evaluate the procedural performance and preliminary outcomes of CEM-Bx performed in our hospital between from September 2021 to June 2022. We reviewed data of 12 women who underwent CEM-Bx during the study period, including their demographic and procedural characteristics, biopsy success rate, histopathological diagnosis, and average glandular dose (AGD). All women (mean age ± standard deviation: 54±6 years) showed enhanced breast lesions on CEM and underwent CEM-Bx within one week. The success rate of CEM-Bx was 100%. The vertical needle approach was used in a decubitus position (N=7, 58%), while the horizontal needle approach was used in an upright sitting position (N=5, 42%). The mean procedure time for the CEM-Bx was 17±6.3 min. The mean AGD was 14.3±12.3 mGy. Histopathologic examination revealed a malignancy rate of 66.7%. In summary, CEM-Bx is a feasible technique, with a high success rate of diagnosing contract-enhanced lesions.

Keywords: Contrast-enhanced mammography (CEM); biopsy; breast cancer; diagnosis; mammography.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://qims.amegroups.com/article/view/10.21037/qims-23-137/coif). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Performance of CEM-Bx by horizontal (above) and vertical (below) needle approaches. (A,E) Scout view imaging at 0 degree; (B,F) pre-fire imaging with stereotactic pair at −15 degree; (C,G): pre-fire imaging with stereotactic pair at 15 degree; (D,H) post-biopsy with marker placement. CEM-Bx, contrast-enhanced mammography-guided biopsy.
See this image and copyright information in PMC

References

    1. Katlynn.rodgers. GE Healthcare receives FDA clearance of the industry’s first contrast-enhanced mammography solution for biopsy. Available online: https://www.ge.com/news/press-releases/ge
    1. Luczyńska E, Heinze S, Adamczyk A, Rys J, Mitus JW, Hendrick E. Comparison of the Mammography, Contrast-Enhanced Spectral Mammography and Ultrasonography in a Group of 116 patients. Anticancer Res 2016;36: 4359-66. - PubMed
    1. Fallenberg EM, Schmitzberger FF, Amer H, Ingold-Heppner B, Balleyguier C, Diekmann F, Engelken F, Mann RM, Renz DM, Bick U, Hamm B, Dromain C. Contrast-enhanced spectral mammography vs. mammography and MRI - clinical performance in a multi-reader evaluation. Eur Radiol 2017;27:2752-64. 10.1007/s00330-016-4650-6 - DOI - PubMed
    1. Jochelson MS, Lobbes MBI. Contrast-enhanced Mammography: State of the Art. Radiology 2021;299:36-48. 10.1148/radiol.2021201948 - DOI - PMC - PubMed
    1. Xing D, Lv Y, Sun B, Xie H, Dong J, Hao C, Chen Q, Chi X. Diagnostic Value of Contrast-Enhanced Spectral Mammography in Comparison to Magnetic Resonance Imaging in Breast Lesions. J Comput Assist Tomogr 2019;43:245-51. 10.1097/RCT.0000000000000832 - DOI - PMC - PubMed